METHOD FOR COMBINED TREATMENT OF UPPER AMPULLARY RECTAL CANCER OF II A-B AND III B STAGE WITH NEGATIVE PROGNOSIS FACTORS AND ABSENCE OF MUTATIONS IN KRAS GENES Russian patent published in 2024 - IPC A61K31/282 A61K31/513 A61K31/506 A61K39/395 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to oncology, and concerns methods of combined treatment of upper ampullary rectal cancer. Preoperative stage involves 2 courses of chemotarget therapy using oxaliplatin in dose of 85 mg/m² intravenously drop-by-drop for 2 hours in 1 day, leucovorin in dose of 400 mg/m² intravenously drop-by-drop for 2 hours in 1 day, 5-fluorouracil in dose of 400 mg/m² intravenously bolus in 1 day and 5-fluorouracil in dose of 2,400 mg/m² intravenously drop-by-drop for 46 hours. That is followed by 4 courses of targeted therapy with cetuximab in dose of 500 mg/m² intravenously for 90 minutes in 1 day in combination with courses of chemotherapy according to the above scheme. Break between the chemotherapy courses is 11 days.

EFFECT: invention provides improved results of combined treatment, reduced toxicity, duration of treatment, increased objective tumour response and frequency of radical operations.

1 cl, 2 ex